Seikagaku and Kaken Pharmaceutical will discontinue development of SI-657, an additional indication of enthesopathy for the ARTZ injectable joint function-improving agent. Kaken is sales partner of ARTZ in Japan.
Enthesopathy refers to a disorder involving the attachment of a tendon or ligament to bone.
The co-development project ends following a lack of clear and sufficient data to support efficacy in the results of a Phase III clinical trial in Japan.
Source: Seikagaku Corporation
Previous collaborations between the two companies include an agreement regarding exclusive marketing rights in Japan for SI-6603, a condoliase injection indicated for the treatment of lumbar disc herniation.
Seikagaku and Kaken Pharmaceutical will discontinue development of SI-657, an additional indication of enthesopathy for the ARTZ injectable joint function-improving agent. Kaken is sales partner of ARTZ in Japan.
Enthesopathy refers to a disorder involving the attachment of a tendon or ligament to bone.
The co-development project ends...
Seikagaku and Kaken Pharmaceutical will discontinue development of SI-657, an additional indication of enthesopathy for the ARTZ injectable joint function-improving agent. Kaken is sales partner of ARTZ in Japan.
Enthesopathy refers to a disorder involving the attachment of a tendon or ligament to bone.
The co-development project ends following a lack of clear and sufficient data to support efficacy in the results of a Phase III clinical trial in Japan.
Source: Seikagaku Corporation
Previous collaborations between the two companies include an agreement regarding exclusive marketing rights in Japan for SI-6603, a condoliase injection indicated for the treatment of lumbar disc herniation.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
